• Science & Technology
• Health & Medicine

No, doctors did not “inject HIV into a dying girl” to treat her cancer

Experimental cancer treatments often hit the headlines, we've taken a look at the science behind a story involving cancer, HIV and the immune system. Experimental cancer treatments often hit the headlines, we've taken a look at the science behind a story involving cancer, HIV and the immune system.

25 June 2013

• Health & Medicine

Cure for young acute myeloid leukaemia patients increases six-fold since 1970s

Almost half of teens and young adults with acute myeloid leukaemia (AML) – a typically aggressive form of leukaemia – are cured thanks to improvements in treatment and care, according to research published in the British Journal of Haematology. Almost half of teens and young adults with acute myeloid leukaemia (AML) – a typically aggressive form of leukaemia – are cured thanks to improvements in treatment and care, according to research published in the British Journal of Haematology.

22 June 2013

• Science & Technology

US researchers unveil womb cancer and acute leukaemia genomes

US researchers have published details of the genetic makeup of two more forms of cancer - acute myeloid leukaemia (AML) and womb (endometrial) cancer. US researchers have published details of the genetic makeup of two more forms of cancer - acute myeloid leukaemia (AML) and womb (endometrial) cancer.

1 May 2013

• Health & Medicine

The challenge of spotting cancers in children

Spotting childhood cancer early has a huge impact on how effectively that cancer can be treated - we cover the important signs for parents to watch out for. Spotting childhood cancer early has a huge impact on how effectively that cancer can be treated - we cover the important signs for parents to watch out for.

24 April 2013

Protein that takes care of our DNA is critical to leukaemia cell survival

A protein – already known to be involved in a cell's response to stress – called Tetratricopeptide repeat domain 5 (TTC5) is critical to the development of acute myeloid leukaemia (AML), according to a new Cancer Research UK study published in Cell Death and Disease A protein – already known to be involved in a cell's response to stress – called Tetratricopeptide repeat domain 5 (TTC5) is critical to the development of acute myeloid leukaemia (AML), according to a new Cancer Research UK study published in Cell Death and Disease

4 April 2013

• Science & Technology
• Health & Medicine

Introducing our latest arsenal in the fight against cancer

25 February 2013

“Dear Cancer, I beat you aged eight and today I got my PhD in cancer research”

We celebrate the achievements of a childhood cancer survivor who's also one of our scientists - read about her experience and what it means to get her PhD. We celebrate the achievements of a childhood cancer survivor who's also one of our scientists - read about her experience and what it means to get her PhD.

12 December 2012

More than 33,000 childhood cancer survivors living in the UK

An estimated 33,000 long-term survivors of childhood cancer - the vast majority of whom are cured - will be living in the UK by the end of 2012. An estimated 33,000 long-term survivors of childhood cancer - the vast majority of whom are cured - will be living in the UK by the end of 2012.

14 November 2012

Smart drug improves survival in older patients with acute myeloid leukaemia

Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their disease, results from a major phase III Cancer Research UK-funded trial led by Cardiff University show today (Saturday). Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their disease, results from a major phase III Cancer Research UK-funded trial led by Cardiff University show today (Saturday).

10 November 2012

• Science & Technology
• Health & Medicine

Notes from NCRI conference (day 4)

7 November 2012

• Health & Medicine

Imatinib - the dawn of targeted treatments

25 October 2012

• Health & Medicine

Drug's 'double hit' overcomes leukaemia resistance

A drug that uses a unique ‘double hit’ to kill leukaemia cells could be a potential new treatment for patients with acute myeloid leukaemia. The research, majority funded by Cancer Research UK, is published this week in Leukaemia. A drug that uses a unique ‘double hit’ to kill leukaemia cells could be a potential new treatment for patients with acute myeloid leukaemia. The research, majority funded by Cancer Research UK, is published this week in Leukaemia.

12 July 2012